Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Tolerability as Well as the Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in LADA Subjects

NCT00058981 is registered in ClinicalTrials.gov with DeveloGen Israel, Ltd. as lead sponsor.

NCT NCT00058981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00058981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Tolerability as Well as the Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in LADA Subjects
Lead sponsor
DeveloGen Israel, Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2002
Completion date
May 31, 2007
Enrollment
100
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, autoimmune